BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

...of Selexys Pharmaceuticals Corp. in 2014 to continue work on Selexys’ SelK2. While Novartis AG later acquired Selexys...
...P selectin (SELP; CD62P) inhibitor crizanlizumab (SEG101), SelK2 had never been on the table (see “Selexys’...
...team wanted to “build the value through Phase II.” Rollins was president and CEO of Selexys...
BioCentury | Jun 29, 2018
Politics & Policy

Sen. Murray confronts BIO, PhRMA over harassment

Weeks after a backlash began against a biotech industry party that featured topless female dancers, Sen. Patty Murray (D-Wash.) sent letters Thursday to the heads of BIO and PhRMA asking what steps they are taking...
BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
BioCentury | Apr 20, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

...CD162; SELPLG) -- spun out of Selexys Pharmaceuticals Corp. in 2014 before Novartis AG (NYSE:NVS; SIX:NOVN) acquired Selexys...
...other asset, crizanlizumab (SEG101), for $240 million up front. Novartis exercised an option to acquire Selexys...
...anti-PSGL-1 mAb can block multiple selectin, not just SELP. Rollins was president and CEO of Selexys...
BioCentury | Apr 18, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

...CD162; SELPLG) -- spun out of Selexys Pharmaceuticals Corp. in 2014 before Novartis AG (NYSE:NVS; SIX:NOVN) acquired Selexys...
...other asset, crizanlizumab (SEG101), for $240 million up front. Novartis exercised an option to acquire Selexys...
...anti-PSGL-1 mAb can block multiple selectin, not just SELP. Rollins was president and CEO of Selexys...
BioCentury | Jan 17, 2018
Company News

Management tracks: NanoString, Orchard

Molecular diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) hired Thomas Bailey as CFO. He was CFO of AgaMatrix Holdings LLC (Salem, N.H.). Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) hired Frank Thomas as CFO and...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...the target. To date Novartis has exercised one -- the acquisition of sickle cell company Selexys Pharmaceuticals Corp....
BioCentury | Jul 7, 2017
Company News

Takeda gains rights to cell banks generated using Selexis' SUREtechnology platform

Selexis S.A. (Geneva, Switzerland) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive rights to access cell banks developed using Selexis' SUREtechnology platform. The pharma will use the technology to develop recombinant fusion proteins. Selexa said the...
BioCentury | Jan 26, 2017
Company News

Novartis mulls Alcon options, reports earnings

...humanized mAb against P selectin ( SELP ; CD62P), by exercising an option to acquire Selexys Pharmaceuticals Corp....
Items per page:
1 - 10 of 38
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

Solid Biosciences Inc. (NASDAQ:SLDB) said COO Alvaro Amorrortu and CMO Chief Jorge Quiroz will step down as the company restructures, reducing its workforce by about one third, to extend its runway. Amorrortu and Quiroz will...
BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

...of Selexys Pharmaceuticals Corp. in 2014 to continue work on Selexys’ SelK2. While Novartis AG later acquired Selexys...
...P selectin (SELP; CD62P) inhibitor crizanlizumab (SEG101), SelK2 had never been on the table (see “Selexys’...
...team wanted to “build the value through Phase II.” Rollins was president and CEO of Selexys...
BioCentury | Jun 29, 2018
Politics & Policy

Sen. Murray confronts BIO, PhRMA over harassment

Weeks after a backlash began against a biotech industry party that featured topless female dancers, Sen. Patty Murray (D-Wash.) sent letters Thursday to the heads of BIO and PhRMA asking what steps they are taking...
BioCentury | Jun 12, 2018
Politics & Policy

BIO chair outraged by nude dancer party

An industry party held during the BIO annual meeting in Boston has been excoriated by the trade organization for featuring nude or partially clothed female dancers. The trade organization’s chairman called on the party’s sponsors...
BioCentury | Apr 20, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

...CD162; SELPLG) -- spun out of Selexys Pharmaceuticals Corp. in 2014 before Novartis AG (NYSE:NVS; SIX:NOVN) acquired Selexys...
...other asset, crizanlizumab (SEG101), for $240 million up front. Novartis exercised an option to acquire Selexys...
...anti-PSGL-1 mAb can block multiple selectin, not just SELP. Rollins was president and CEO of Selexys...
BioCentury | Apr 18, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

...CD162; SELPLG) -- spun out of Selexys Pharmaceuticals Corp. in 2014 before Novartis AG (NYSE:NVS; SIX:NOVN) acquired Selexys...
...other asset, crizanlizumab (SEG101), for $240 million up front. Novartis exercised an option to acquire Selexys...
...anti-PSGL-1 mAb can block multiple selectin, not just SELP. Rollins was president and CEO of Selexys...
BioCentury | Jan 17, 2018
Company News

Management tracks: NanoString, Orchard

Molecular diagnostics company NanoString Technologies Inc. (NASDAQ:NSTG) hired Thomas Bailey as CFO. He was CFO of AgaMatrix Holdings LLC (Salem, N.H.). Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) hired Frank Thomas as CFO and...
BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...the target. To date Novartis has exercised one -- the acquisition of sickle cell company Selexys Pharmaceuticals Corp....
BioCentury | Jul 7, 2017
Company News

Takeda gains rights to cell banks generated using Selexis' SUREtechnology platform

Selexis S.A. (Geneva, Switzerland) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive rights to access cell banks developed using Selexis' SUREtechnology platform. The pharma will use the technology to develop recombinant fusion proteins. Selexa said the...
BioCentury | Jan 26, 2017
Company News

Novartis mulls Alcon options, reports earnings

...humanized mAb against P selectin ( SELP ; CD62P), by exercising an option to acquire Selexys Pharmaceuticals Corp....
Items per page:
1 - 10 of 38